Sarepta Therapeutics (SRPT) Stock Price, News & Analysis

Company Overview

Sarepta Therapeutics, Inc. is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S. Food and Drug Administration for specific DMD mutations. Exondys 51 (eteplirsen), Vyondys 53 (golodirsen) and Amondys 45 (casimersen) use chemically modified oligonucleotides to induce exon skipping and restore production of functional dystrophin protein. In addition, Elevidys (delandistrogene moxeparvovec) is an adeno-associated virus (AAV)-based gene therapy designed to deliver a shortened dystrophin gene to muscle tissue, representing one of the first approved gene therapies for DMD.

Founded in the late 1980s under the name AVI BioPharma and rebranded as Sarepta Therapeutics in 2012, the company initially explored antiviral technologies before pivoting to neuromuscular disease in 2010. Sarepta now maintains commercial operations across North America and has established collaborations in Europe and Asia to support clinical trials and regulatory filings. The company continues to expand its pipeline, exploring next-generation gene editing, microdystrophin constructs and treatments for other genetic muscle disorders such as limb-girdle muscular dystrophy.

Leadership at Sarepta is spearheaded by President and Chief Executive Officer Douglas Ingram, who joined the company in 2018 and assumed the CEO role in 2021. Under his guidance, Sarepta has grown from a single-product organization into a multi-asset innovator with a broad platform in precision genetic medicine. The company’s executive team combines expertise in neurology, genetic engineering and regulatory affairs to advance therapies from early-stage research through global commercialization.

Key Stats

• Today's Range: $15.42 to $16.28
• 50-Day Range: $15.55 to $23.23
• 52-Week Range: $10.41 to $40.90
• Volume: 2.44 million shs
• Average Volume: 2.94 million shs
• Market Capitalization: $1.68 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $24.77
• Consensus Rating: Hold

Sarepta Therapeutics Stock Analysis - MarketRank™

Sarepta Therapeutics scored higher than 74% of companies evaluated by MarketBeat, and ranked 251st out of 865 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Hold

Consensus Rating

Sarepta Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.07, and is based on no strong buy ratings, 8 buy ratings, 13 hold ratings, and 6 sell ratings.

Upside Potential

Sarepta Therapeutics has a consensus price target of $24.77, representing about 55.9% upside from its current price of $15.89.

Amount of Analyst Coverage

Sarepta Therapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: -34.84%

Earnings Growth

Earnings for Sarepta Therapeutics are expected to decrease by -34.84% in the coming year, from $3.99 to $2.60 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Sarepta Therapeutics is -16.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Sarepta Therapeutics is -16.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Growth Ratio

Sarepta Therapeutics has a PEG Ratio of 0.17. PEG Ratios below 1 indicate that a company could be undervalued.

Price to Book Value per Share Ratio

Sarepta Therapeutics has a P/B Ratio of 1.46. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

25.45% of the float of Sarepta Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Sarepta Therapeutics has a short interest ratio ("days to cover") of 7.32.

Change versus previous month

Short interest in Sarepta Therapeutics has recently increased by 0.40%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Sarepta Therapeutics does not currently pay a dividend.

Dividend Growth

Sarepta Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 4.2 / 5
• News Sentiment: 0.73

News Sentiment

Sarepta Therapeutics has a news sentiment score of 0.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 13 news articles for Sarepta Therapeutics this week, compared to 11 articles on an average week.

Search Interest

47 people have searched for SRPT on MarketBeat in the last 30 days. This is an increase of 124% compared to the previous 30 days.

MarketBeat Follows

11 people have added Sarepta Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 175% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Sarepta Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $123,208.00 in company stock.

Percentage Held by Insiders

6.90% of the stock of Sarepta Therapeutics is held by insiders.

Percentage Held by Institutions

86.68% of the stock of Sarepta Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/06/2026
• Today: 6/09/2026
• Next Earnings (Estimated): 8/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SRPT
• Previous Symbol: NASDAQ:AVII
• CIK: 873303
• Web: www.sareptatherapeutics.com
• Phone: (617) 274-4000
• Fax: 425-354-5038
• Employees: 1,372
• Year Founded: 1980

Price Target and Rating

• Average Price Target for Sarepta Therapeutics: $24.77
• High Price Target: $50.00
• Low Price Target: $13.00
• Potential Upside/Downside: +55.9%
• Consensus Rating: Hold
• Rating Score (0-4): 2.07
• Research Coverage: 27 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.96)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 3.98
• P/E Growth: 0.17
• Net Income: -$713.41 million
• Net Margins: -2.94%
• Pretax Margin: 1.12%
• Return on Equity: 7.56%
• Return on Assets: 2.94%

Debt

• Debt-to-Equity Ratio: 0.56
• Current Ratio: 4.63
• Quick Ratio: 2.62

Sales & Book Value

• Annual Sales: $2.18 billion
• Price / Sales: 0.77
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $10.89 per share
• Price / Book: 1.46

Miscellaneous

• Outstanding Shares: 105,576,000
• Free Float: 98,291,000
• Market Cap: $1.68 billion
• Optionable: Optionable
• Beta: 0.21